PipelineReview.com. Biopharmaceutical News & Clinical Trials
WEBPipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
All news - Pipelinereview
WEB2 days ago · PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie Publishing - Ulrich Martin Veinat Puigsec - Can Magí s/n | 17862 Vallfogona de Ripollès | Spain | T +34-87-200 1365 | Email [email protected]
Johnson & Johnson seeks first EU approval of nipocalimab to treat …
WEBSep 12, 2024 · Marks first EMA submission for nipocalimab, an investigational treatment that binds with high affinity and specificity to block FcRn and reduce levels of autoantibodies
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery …
WEBSep 16, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.
TREMFYA® (guselkumab) receives U.S. FDA approval for adults …
WEBSep 12, 2024 · The first and only dual-acting interleukin-23 inhibitor approved in active ulcerative colitis, TREMFYA ® showed highly statistically significant rates of endoscopic remission at one year in the pivotal QUASAR program 1,2,3,4,5. TREMFYA ® is now approved for the treatment of plaque psoriasis, active psoriatic arthritis and ulcerative colitis. HORSHAM, PA, USA I September 11, 2024 I Johnson ...
Absci Initiates IND-Enabling Studies for ABS-101, a
WEBFeb 22, 2024 · IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after. VANCOUVER, Canada and NEW YORK, NY, USA I February 21, 2024 I Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the initiation of IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody designed using Absci’s de novo generative AI ...
Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and …
WEBJul 1, 2024 · Idorsia receives approval from the European Commission (EC) for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.; JERAYGO is a new oral antihypertensive therapy – the first in almost 40 years – that is working via a new therapeutic pathway.
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based …
WEBAug 15, 2024 · PASADENA, CA, USA I August 14, 2024 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented preclinical data and detailed its plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduce body ...
TORL BioTherapeutics Presents Updated Phase 1 Results of Novel …
WEBSep 16, 2024 · TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer
Vivani Medical Announces FDA Clears Investigational New Drug ...
WEBJun 13, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of our expertise.